The National Institutes of Health (NIH)


Research (R, P, D and U Announcements)


(R21) Oct 16, Feb 16, June 16

NIH Pathway to Independence Award (Parent K99/R00)

Title (Activity Code) Deadline Announcement Number
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) February 19, 2016 RFA-CA-16-005
Collaborative Activities to Promote Metabolomics Research (Admin Supp) February 15, 2016 PA-16-005
Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01) Feb 5, June 5, Oct 5 PA-15-347
NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03) Feb 16,June 16, Oct 16 PAR-15-344
Administrative Supplements for Research on Sex/Gender Differences (Admin Supp) March 4, 2016 PAR-15-344PA-16-066
NIH Pathway to Independence Award (Parent K99/R00) Feb 12, June 12, Oct 12 PA-16-077
Clinical Sites for the IDeA States Pediatric Clinical Trials Network (UG1) March 15, 2016- Letter of Intent
April 15, 2016, by 5:00 PM local time of applicant organization- Application
RFA-OD-16-001
Data Coordinating and Operations Center for the IDeA States Pediatric Clinical Trials Network (U24) March 15, 2016- Letter of Intent
April 15, 2016, by 5:00 PM local time of applicant organization- Application
RFA-OD-16-002
Environmental Influences on Child Health Outcomes: Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core) (U24) March 15, 2016- Letter of Intent
April 15, 2016, by 5:00 PM local time of applicant organization- Application
RFA-OD-16-003
Environmental influences on Child Health Outcomes (ECHO) Pediatric Cohorts (UG3/UH3) March 15, 2016- Letter of Intent
April 15, 2016, by 5:00 PM local time of applicant organization- Application
RFA-OD-16-004
Environmental Influences on Child Health Outcomes (ECHO) Data Analysis Center (U24) March 15, 2016- Letter of Intent
April 15, 2016, by 5:00 PM local time of applicant organization- Application
RFA-OD-16-005
Environmental Influences on Child Health Outcomes (ECHO) Coordinating Center (U2C) March 15, 2016- Letter of Intent
April 15, 2016, by 5:00 PM local time of applicant organization- Application
RFA-OD-16-006
Limited Competition: Exposure Analysis Services for the Environmental Influences on Children’s Health Outcomes (ECHO) Program (Admin Supplement) March 15, 2016- Letter of Intent
April 15, 2016, by 5:00 PM local time of applicant organization- Application
PA-16-046
Imaging Diagnostics of Dental Diseases and Conditions (Caries, Periodontal Disease, Cracked Teeth, and Pulp Vitality) (R43/R44) (R41/R42) Oct 5, Feb 5, June 5 (R43/R44) PA-15-335
(R41/R42) PA-15-336
Advanced Development of Informatics Technologies for Cancer Research and Management (U24) November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018 PAR-15-331
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01) November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018 PAR-15-332
Sustained Support for Informatics Resources for Cancer Research and Management (U24) November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018 PAR-15-333
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21) November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018 PAR-15-334
Oral HIVacc: Oral Mucosal Immunization Approaches for HIV Prevention (R01) Letter of Intent- October 24, 2015
Application- November 24, 2015
RFA-DE-16-006
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp) Due dates may vary by awarding IC PA-15-322
Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp) Due dates may vary by awarding IC PA-15-321
Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions(R01) (R21) (R01) PAR-13-379
(R21) PAR-13-380
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp) June 30, 2015, Oct 31, 2015 PA-13-381
Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01)(R21) (R21) July 16, Nov 16, Mar 16 PAR-13-380
Biological and Physiological Effects of E-cigarette Aerosol Mixtures (R01)(R21) July 28, 2015 (R01)RFA-DE-16-004 (R21)RFA-DE-16-005
AHRQ Conference Grant Program (R13) Aug 1, Nov 1, Feb 1, May 1 PA-13-017
NIH Support for Conferences and Scientific Meetings (Parent R13/U13) Aug 12, Dec 12, Apr 12 PA-13-347
Minor Use Minor Species Development of Drugs- Research Project Grant (R01) August 14, 2015; January 15, 2016; August 12, 2016; January 13, 2017; August 11, 2017; January 12, 2018 RFA-FD-15-004
National Cancer Institute Program Project Applications (P01) Sept 25, Jan 25, May 25 PAR-15-023
Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)(R21)(R24) Sept 25, Jan 25, May 25 (R24) PAR-13-252
Resource Related Research Projects for Development of Animal Models and Related Materials (R01)(R21)(R24) Sept 25, Jan 25, May 25 (R24) Jan 25, May 25, Sept 25
Cancer Education Grants Program (R25) Sept 25, Jan 25, May 25 PAR-12-049
Early-life Factors and Cancer Development Later in Life (R01, R03, R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-15-126
Establishing Behavioral and Social Measures for Causal Pathway Research in Dental, Oral and Craniofacial Health (R21)(R01) (R01) Oct 5, Feb 5, June 5 (R01) PAR-14-143
Immune System Plasticity in the Pathogenesis and Treatment of Complex Dental, Oral, and Craniofacial Diseases (R01) Oct 5, Feb 5, June 5 PAR-15-192
NIDCR Clinical Trial or Biomarker Clinical Validation Study Cooperative Agreement (U01) Oct 5, Feb 5, June 5 PAR-15-059
Advancing Interventions to Improve Medication Adherence (R01) Oct 5, Feb 5, June 5 PA-14-334
Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01) Oct 5, Feb 5, June 5 PA-15-058
Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01) Oct 5, Feb 5, June 5 PA-14-177
Self-Management for Health in Chronic Conditions (R01) Oct 5, Feb 5, June 5 PA-14-344
Biology of the Temporomandibular Joint in Health and Disease (R01) Oct 5, Feb 5, June 5 PA-14-358
Discovery of in vivo Chemical Probes (R01) Oct 5, Feb 5, June 5 PAR-14-279
Understanding and Promoting Health Literacy (R01) (R03) (R21) (R01) Oct 5, Feb 5, June 5 (R01) PAR-13-130
Mechanisms, Models, Measurement, & Management in Pain Research (R01) (R03) (R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-13-118
Research on Ethical Issues in Biomedical, Social, and Behavioral Research (R01) (R03) (R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-11-180
Identifying Non-coding RNA Targets for Early Detection of Cancer (R01) (R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-12-213
Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R01) Oct 5, Feb 5, June 5 PA-14-155
Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01)(R21) (R01) Oct 5, Feb 5, June 5 (R01) PAR-13-379
Nutrition and Alcohol-Related Health Outcomes (R01, R03, R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-13-359
Research on the Health of LGBTI Populations (R01, R03, R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-12-111
Biomarkers for Early Detection of Hematopoietic Malignancies (R01) (R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-12-221
Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)(R21)(R24) (R01) Oct 5, Feb 5, June 5 (R01) PAR-13-114
NIDCR Clinical Trial Implementation or Biomarker Clinical Evaluation Study Cooperative Agreement (U01) Oct 5, Feb 5, June 5 PAR-11-339
Bioengineering Research Grants (BRG) (R01) Oct 5, Feb 5, June 5 PAR-13-137
Systems Science and Health in the Behavioral and Social Sciences (R01) Oct 5, Feb 5, June 5 (R01) PAR-15-048
Dissemination and Implementation Research in Health (R21)(R03)(R01) (R01) Oct 5, Feb 5, June 5 (R01) PAR-13-374
Modeling Social Behavior (R01) Oct 5, Feb 5, June 5 PAR-13-374
Research on Malignancies in the Context of HIV/AIDS (R01) Oct 5, Feb 5, June 5 PA-13-377
Research Project Grant (Parent R01) Oct 5, Feb 5, June 5 PA-13-302
Genetic Susceptibility and Variability of Human Structural Birth Defects (R01) Oct 5, Feb 5, June 5 PA-14-056
Mechanisms of Alcohol-associated Cancers (R01) and Mechanisms of Alcohol-associated Cancers (R21) (R01) Oct 5, Feb 5, June 5 (R01) PA-12-146
NIH Director’s New Innovator Award Program (DP2) October 16, 2015 RFA-RM-13-007
Early-life Factors and Cancer Development Later in Life (R03, R21) (R21) (R03) Oct 16, Feb 16, June 16 (R03) PA-15-124
(R21) PA-15-125
Establishing Behavioral and Social Measures for Causal Pathway Research in Dental, Oral and Craniofacial Health (R21)(R01) (R21) Oct 16, Feb 16, June 16 (R21) PAR-14-144
Immune System Plasticity in the Pathogenesis and Treatment of Complex Dental, Oral, and Craniofacial Diseases (R21) Oct 16, Feb 16, June 16 PAR-15-193
Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R21) Oct 16, Feb 16, June 16 PA-15-057
NIDCR Clinical Trial or Biomarker Clinical Validation Study Planning Grant (R34) Oct 16, Feb 16, June 16 PAR-14-346
NIDCR Behavioral or Social Intervention Clinical Trial Planning Grant (R34) Oct 16, Feb 16, June 16 PAR-14-342
Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21) Oct 16, Feb 16, June 16 PA-14-176
Advancing Interventions to Improve Medication Adherence (R21) Oct 16, Feb 16, June 16 PA-14-335
Biology of the Temporomandibular Joint in Health and Disease (R21) Oct 16, Feb 16, June 16 PA-14-359
Self-Management for Health in Chronic Conditions (R21) Oct 16, Feb 16, June 16 PA-14-343
Understanding and Promoting Health Literacy (R01) (R03) (R21) (R21) Oct 16, Feb 16, June 16 (R21) PAR-13-132
Mechanisms, Models, Measurement, & Management in Pain Research (R01) (R03) (R21) (R03) Oct 16, Feb 16, June 16 
(R21) Oct 16, Feb 16, June 16
(R03) PA-13-117
(R21) PA-13-119
Research on Ethical Issues in Biomedical, Social, and Behavioral Research (R01) (R03) (R21) (R03) Oct 16, Feb 16, June 16
(R21) Oct 16, Feb 16, June 16
(R03) PA-11-181
(R21) PA-11-182
Identifying Non-coding RNA Targets for Early Detection of Cancer (R01) (R21) (R21) Oct 16, Feb 16, June 16 (R21) PA-12-214
Nutrition and Alcohol-Related Health Outcomes (R01, R03, R21) (R03) Oct 16, Feb 16,June 16 
(R21) Oct 16, Feb 16, June 16
(R03) PA-13-360
(R21) PA-13-361
Mechanisms of Alcohol-associated Cancers (R01) and Mechanisms of Alcohol-associated Cancers (R21) (R21) Oct 16, Feb 16, June 16 (R21)PA-12-147
Research on the Health of LGBTI Populations (R01, R03, R21) (R03) Oct 16, Feb 16, June 16 
(R21) Oct 16, Feb 16, June 16
(R03) PA-12-112
(R21) PA-12-113
Biomarkers for Early Detection of Hematopoietic Malignancies (R01) (R21) (R21) Oct 16, Feb 16, June 16 (R21) PA-12-220
Research on Malignancies in the Context of HIV/AIDS (R21) Oct 16, Feb 16, June 16 PA-13-378
Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)(R21)(R24) (R21) Oct 16, Feb 16,  June 16 (R21) PAR-13-115
Systems Science and Health in the Behavioral and Social Sciences (R21) (R21) Oct 16, Feb 16, June 16 (R21) PAR-15-047
Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R01)(R21) (R21) Oct 16, Feb 16, June 16 (R21) PA-13-288
Dissemination and Implementation Research in Health (R21)(R03)(R01) (R03) Oct 16, Feb 16,  June 16
(R21) Oct 16, Feb 16, June 16
(R03) PAR-13-056
(R21) PAR-13-054
Exploratory/Developmental BioengineeringResearch Grants (EBRG) [R21] Oct 16, Feb 16, June 16 PA-12-284
NIDCR Small Grant Program for New Investigators (R03) Oct 16, Feb 16, June 16 PAR-13-348
NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03) Oct 16, Feb 16, June 16 PAR-13-044
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21) Oct 16, Feb 16, June 16 PA-12-284
Development of Animal Models and Related Biological Materials for Research (R21) Oct 16, Feb 16, June 16 PA-13-145
NIDCR Small Research Grants for Secondary Analysis of FaceBase Data (R03) Oct 16, Feb 16, June 16 PAR-13-178
NIH Small Research Grant Program (Parent R03) New: Oct 16, Feb 16, June 16
Resubmission/ Revision: Nov 16, Mar 16, July 16
PA-13-304
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21) Oct 16, Feb 16, June 16 PA-12-284
Academic Research Enhancement Award (Parent R15) Oct 25, Feb 25, June 25 PA-13-313
Academic Research Enhancement Award Oct 25, Feb 25, June 25 PA-13-303
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21) Nov 30, 2015; June 22, 2016; Nov 30, 2016 PAR-15-053
Imaging and Biomarkers for Early Cancer Detection (R01) Dec 11, 2015 PAR-13-189
Detection of Pathogen-Induced Cancer (DPIC)(R01) Dec 11, 2015 PAR-13-190
Interventions for Health Promotion and Disease prevention in Native American Populations (R01) May 12, 2016; May 12, 2017 PA-14-260
NIH Science Education Partnership Award (SEPA) (R25) June 22, 2016 PAR-14-228
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp) Due dates may vary by awarding IC PA-12-149
Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers Due dates may vary by awarding IC PA-12-150

Fellowship (F) Announcements


Title (Activity Code) Deadline Announcement Number
Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35) Sept 25, Jan 25, May 25 PA-14-016
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32) Sept 25, Jan 25, May 25 PA-14-015
Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD and Other Dual Doctoral Degree Fellows (Parent F30) New: Oct 12, Feb 12, June 12
Renewal: Nov 12, Mar 12, July 12
PA-14-150
Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) New: Oct 12, Feb 12, June 12
Renewal: Nov 12, Mar 12, July 12
PA-14-147
Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellowships to Promote Diversity in Health-Related Research (Parent F31 – Diversity) New: Oct 12, Feb 12, June 12
Renewal: Nov 12, Mar 12, July 12
PA-14-148
Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows (Parent F32) New: Oct 12, Feb 12, June 12
Renewal: Nov 12, Mar 12, July 12
PA-14-149
Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellows (Parent F33) New: Oct 12, Feb 12, June 12,
Renewal: Nov 12, Mar 12, July 12
PA-14-151

Career (K) Announcements


Title (Activity Code) Deadline Announcement Number
Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23) Oct 12, Feb 12, June 12 PAR-15-062
NCI Transition Career Development Award to Promote Diversity (K22) Oct 12, Feb 12, June 12 PAR-15-063
Mentored Research Scientist Development Award to Promote Diversity (K01) Oct 12, Feb 12, June 12 PAR-15-064
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) Oct 12, Feb 12, June 12 PAR-15-060
The NCI Transition Career Development Award (K22) Oct 12, Feb 12, June 12 PAR-15-056
Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07) Oct 12, Feb 12, June 12 PAR-15-033
Investigator Award in Patient-Oriented Research (Parent K24) Oct 12, Feb 12, June 12 PA-14-047
Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18) Oct 12, Feb 12, June 12 PAR-14-039
Independent Scientist Award (Parent K02) Oct 12, Feb 12, June 12 PA-14-045
Mentored Clinical Scientist Research Career Development Award (Parent K08) Oct 12, Feb 12, June 12 PA-14-046
Mentored Patient-Oriented Research Career Development Award (Parent K23) Oct 12, Feb 12, June 12 PA-14-049
Mentored Quantitative Research Development Award (Parent K25) Oct 12, Feb 12, June 12 PA-14-048
NIDCR Dentist-Scientist Pathway to Independence Award (K99/R00) Oct 12, Feb 12, June 12 PAR-14-057

Training (T) Announcements


Title (Activity Code) Deadline Announcement Number
Revisions to Add Biomedical Big Data Training to Active Institutional Training Grants (T32) July 27, 2015;
July 28, 2016
RFA-HG-14-005
Predoctoral Training in Biomedical Big Data Science (T32) July 27, 2015;
July 28, 2016
RFA-HG-14-004

 Loan Repayment Program (LRP) Announcements


Title (Activity Code) Deadline Announcement Number

Research (R) Announcements


Title: The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
Announcement Number: RFA-CA-16-005
Deadline: February 19, 2016, by 5:00 PM local time of applicant organization.
Purpose: The objective of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage outstanding, late-stage graduate students with a demonstrated potential and interest in pursuing careers as independent researchers by facilitating the successful transition to their postdoctoral positions.The F99/K00 award is intended for individuals who require 1-2 years to complete their Ph.D. dissertation research training (F99 phase) before transitioning to mentored postdoctoral research training (K00 phase). Consequently, applicants are expected to propose an individualized research training plan for the next 1-2 years of dissertation research training and a plan for 3-4 years of mentored postdoctoral research and career development activities that will prepare them for independent cancer-focused research careers.
Award: For the F99 phase, award budgets are composed of stipends, tuition and fees, and institutional allowance, as described below. For the K00 phase, award budgets are composed of salaries and fringe benefits, tuition and fees, research and career development support, and indirect costs.For the F99/K00 award, individuals may receive up to 6 years combined support for both phases, which includes up to 2 years in the F99 fellowship phase and up to 4 years in the K00 career development phase.
Eligibility & Guidelines: Here
Announcement Expires: February 20, 2016


Title: Collaborative Activities to Promote Metabolomics Research (Admin Supp)

Announcement Number: PA-16-005

Deadline: February 15, 2016

Purpose: This Administrative Supplement funding opportunity is part of the Common Fund Metabolomics Program created to increase and improve the nation’s ability to undertake metabolomics analyses in translational and clinical research. Metabolomics has great potential to advance our understanding of human diseases, but requires specialized expertise in metabolomics study design, technology, and data analysis and interpretation. This FOA supports supplemental funds to current NIH-funded research projects for new interactive collaborations between basic or clinical researchers and metabolomics experts to add a metabolomics approach to the existing Research Strategy for the project. In addition to enhancing the parent grant by adding metabolomics analyses, collaborative projects must include activities to increase the expertise of the biomedical research group in key aspects of metabolomics study design, analysis, and data interpretation.

Award: Application budgets are limited to no more than $100,000 direct costs, exclusive of consortium/contractual Facilities and Administrative (F&A) costs, and must reflect the actual needs of the proposed project.

The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes.

Eligibility & Guidelines: Here

Announcement Expires:  February 16, 2016


Title: Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01)

Announcement Number: PA-15-347

Deadline: February 5, June 5, October 5 Standard dates apply, by 5:00 PM local time of applicant organization

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality.  Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch.  Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation.  This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs).  The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities.

Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Eligibility & Guidelines: Here

Announcement Expires:  January 8, 2019


Title: NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03)

Announcement Number: PAR-15-344

Deadline: by 5:00 PM local time of applicant organization

Purpose: The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.

Award: A budget for direct costs of up to $100,000 per year, with a maximum of $200,000 over two years, may be requested. The total project period for an application submitted in response to this funding opportunity may not exceed two years.

Eligibility & Guidelines: Here

Announcement Expires: September 8, 2018


Title: Administrative Supplements for Research on Sex/Gender Differences (Admin Supp)

Announcement Number: PA-16-066

Deadline: March 4, 2016, by 5:00 PM local time of applicant organization.

Purpose: The Office of Research on Women’s Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender differences (or similarities) and/or sex and gender factors in human health and illness, including basic, preclinical, clinical and behavioral studies. Of special interest are studies relevant to understanding of the significance of biological sex on cells; comparative studies of male and female tissues, organ systems and physiological systems; sex based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women’s Health Research.

Award: Each administrative supplement has a maximum total award of $100,000.  Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. The project and budget periods must be within the currently approved project period for the existing parent award.

Eligibility & Guidelines: Here

Announcement Expires: March 5, 2016


Title: NIH Pathway to Independence Award (K99/R00)

Announcement Number: PA-16-077

Deadline: Standard dates apply: Link

New: February 12, June 12, October 12

Resubmission, Revision: March 12, July 12, Nov 12

Purpose: The intent of the K99/R00 program is to assist new investigators in transitioning to stable independent research positions at an earlier age and with an enhanced probability of success in obtaining independent NIH or other independent research support.

The K99/R00 award will provide up to 5 years of support consisting of two phases:

  • The initial mentored phase will provide support for up to 2 years for the most promising and exceptionally talented new investigators who have no more than 5 years of postdoctoral research training experience at the time of initial application or subsequent resubmission(s) and do not already have a full-time tenure track assistant professor position (or equivalent).
  • Following the mentored phase, the individual may request up to 3 years of support to conduct research as an independent scientist at an extramural sponsoring institution/organization to which the individual has been recruited, been offered and has accepted a tenure-track full-time assistant professor position (or equivalent). This support is to allow the individual to continue to work toward establishing his/her own independent research program and prepare an application for regular research grant support (R01). Support for the independent phase, however, is not automatic and is contingent upon being accepted by an appropriate extramural institution and the successful NIH programmatic review of the individual’s mentored phase of the award.

Award: Mentored Phase (K99)

Salary and research costs may be requested to the level provided by the awarding Institute or Center. Candidates should consult the following table for IC-specific, programmatic and budgetary information (see Table of IC-Specific Information, Requirements and Staff Contacts).

Intramural: Mentored candidates in the NIH intramural program will be supported by intramural funds provided by the NIH Institute/Center intramural laboratory in which they are conducting their research. Budget details for the mentored phase will be negotiated with the sponsoring intramural laboratory. Salary will be consistent with that offered scientists in similar, intramural NIH positions.

Extramural: Mentored candidates at an extramural sponsoring institution/organization will be supported by NIH extramural funds. The requested salary must be consistent both with the established salary structure at the institution and with salaries actually provided by the institution from its own funds to other staff members with equivalent qualifications, rank, and responsibilities in the department concerned. The total salary requested must be based on a full-time, 12-month staff appointment. For information regarding NIH policy on determining full-time professional effort for career awards, see NOT-OD-04-056. If full-time, 12-month salaries are not currently paid to comparable staff members, the salary proposed must be related appropriately to the existing salary structure. Confirmation of salary is required prior to the issuance of an award. Fringe benefits based on the sponsoring institution’s rate and the percent of effort are provided in addition to the salary.

The extramural sponsoring institution may supplement the NIH salary contribution up to a level that is consistent with the institution’s salary scale. However, supplementation may not be from Federal funds unless specifically authorized by the Federal program from which such funds are derived. In no case may PHS funds be used for salary supplementation. Institutional supplementation of salary must not require extra duties or responsibilities that would interfere with the purpose of the career award. The total salary may not exceed the legislatively mandated salary cap. 

Independent Phase (R00)

The total cost for the independent phase (R00) may not exceed $249,000 per year. This amount includes salary, fringe benefits, research costs, and applicable indirect costs. Indirect costs will be reimbursed at the extramural sponsoring institution’s indirect cost rate. Indirect costs requested by consortium participants are included in the total cost limitation.

Eligibility & Guidelines: Here

Announcement Expires:  May 8, 2016


Title: Clinical Sites for the IDeA States Pediatric Clinical Trials Network (UG1)
Announcement Number: RFA-OD-16-001
Deadline: March 15, 2016- Letter of IntentApril 15, 2016, by 5:00 PM local time of applicant organization- Application
Purpose: This funding opportunity announcement (FOA) intends to provide clinical investigators and their support teams in an Institutional Development Awards Program (IDeA) academic research setting the necessary professional development, infrastructure and capacity building to conduct pediatric clinical trials research for children with a variety of conditions. The IDeA States Pediatric Clinical Trials Network (ISPCTN) is being developed to foster study of any diseases and conditions relevant to the pediatric population, but priority will be given to the four focus areas of the Environmental influences on Child Health Outcomes (ECHO) Program (RFA-OD-16-004) which include: 1) upper and lower airway disease; 2) obesity; 3) pre-, peri-, and postnatal outcomes; and 4) neurodevelopment.
Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.The NIH intends to commit up to $30,000,000 in FY 2016 to fund up to 15 awards. These will be multiyear funded awards beginning in FY2016. Applicants may request direct cost budgets of up to $315,000 for each of the four years of the award. The application should include a complete detailed budget for each year of study.  These are four year awards. No cost extensions are limited to up to only 8 months (10/30/2020) with this award.
Eligibility & Guidelines: Link
Announcement Expires:  April 16, 2016


Title: Data Coordinating and Operations Center for the IDeA States Pediatric Clinical Trials Network (U24)Announcement Number: RFA-OD-16-002

Deadline: March 15, 2016- Letter of Intent

April 15, 2016, by 5:00 PM local time of applicant organization- Application

Purpose: The purpose of this funding opportunity announcement (FOA) is to invite applications for a centralized Data Coordinating and Operations Center (DCOC) to support the activities of the IDeA States Pediatric Clinical Trials Network (ISPCTN). The funded DCOC will cooperate with the ISPCTN Program Directors/Principal Investigators (PDs/PIs), the NICHD and NIGMS Project Scientists, and the NICHD Program Officer, to identify pediatric clinical trials that are relevant and feasible to implement in the ISPCTN, establish collaborations and partnerships, design or adapt protocols appropriate to generate high quality data, develop and implement quality assurance and quality control measures, establish and maintain human subject protection oversight, comply with applicable policies, regulations, and laws for the research project, and develop and implement relevant professional development programs. The DCOC will have primary responsibility for resource allocation, data management and analysis and data sharing for research conducted through the Network, in collaboration with the ISPCTN Steering Committee and NIH Program Staff. The ISPCTN is being developed as a separate, but related program to the Environmental influences on Child Health Outcomes (ECHO) Program. The ECHO Program intends to investigate the longitudinal impact of pre-, peri-, and postnatal environmental exposures on pediatric health outcomes with high public health impact. The ISPCTN will be designed to study any diseases and conditions relevant to the pediatric population, but priority will be given to the four focus areas of the ECHO Program which include: 1) upper and lower airway disease; 2) obesity; 3) pre-, peri-, and postnatal outcomes; and 4) neurodevelopment.

Award: The number of planned awards is one, although it may be split or shared, contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

The NIH intends to commit up to $ 45,000,000 in FY 2016 to fund one four year award. This will be a multiyear funded award beginning in FY2016.

An applicant for the DCOC may request a budget for up to $2,500,000 per year in direct costs plus $4,530,000 per year in direct costs for capitation fees for distribution to the Clinical Sites, and for necessary monitoring, DSMB visits, and Scientific Oversight Board activities. An applicant for the DCOC should request a project period of four years. No cost extensions are limited to up to only 8 months (5/30/2020) with this award.

Eligibility & Guidelines: Link

Announcement Expires: April 16, 2016


Title: Environmental Influences on Child Health Outcomes: Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core) (U24)Announcement Number: RFA-OD-16-003

Deadline: March 15, 2016- Letter of Intent

April 15, 2016, by 5:00 PM local time of applicant organization- Application

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Environmental influences on Child Health Outcomes (ECHO) Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core). Working collaboratively with the other members of the ECHO Consortium and the Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (see below), the ECHO PRO Core will conduct research (including development and validation of new instruments) and provide research services and resources to all ECHO Cohort Sites and Centers.  The ECHO PRO Core will provide psychometric and medical expertise in the development, selection and use of PROs, child patient reported outcomes (cPROs), and proxy PROs for the evaluation of health and disease in children and other subjects being studied by the ECHO Cohort Sites.

This FOA is one of seven companion FOAs that will establish the elements of the ECHO Consortium. Clinical Sites will collect clinical data and specimens from well-characterized participants. A Data Analysis Center (DAC) will oversee data standardization, integration, and storage, and will implement data sharing and computational tools for the integrated analysis of clinical and laboratory data. Overall coordination will be provided by an ECHO Coordinating Center (CC).

Awardees will comprise the ECHO Consortium and must work collaboratively to plan and execute a large study to discover and characterize the impact of the environment on child health and disease. The product will be a publically available data resource that will enhance and accelerate subsequent mechanistic research on childhood diseases and conditions affected by environmental influences.

Award: NIH intends to fund an estimate of 1 award in FY2016. The amount of funds available is up to $2M total costs for FY2016, and a total of approximately $23M for fiscal years 2017-2022. Actual amounts will depend on annual appropriations. Application budgets are not limited, but need to reflect the actual needs of the proposed project.

Eligibility & Guidelines: Link

Announcement Expires: April 16, 2016


Title: Environmental influences on Child Health Outcomes (ECHO) Pediatric Cohorts (UG3/UH3)

Announcement Number: RFA-OD-16-004

Deadline: March 15, 2016- Letter of Intent

April 15, 2016, by 5:00 PM local time of applicant organization- Application

Purpose: This Funding Opportunity Announcement (FOA) is soliciting applications to support existing cohorts to address how pre-, peri-, and post-natal environmental exposures impact childhood development and health outcomes as part of the Environmental influences on Child Health Outcomes (ECHO) program. Increasing evidence suggests that exposures early in life (e.g. nicotine, diet, microbiome) can result in health deficits and lead to life-long consequences. The purpose of this FOA is to leverage and build upon existing cohort infrastructure to prospectively investigate the role of early life exposures and underlying biological mechanisms in childhood health and disease.

This FOA runs in parallel with companion FOAs that solicit applications for the Coordinating Center (RFA-OD-16-006), Data Analysis Center (RFA-OD-16-005), Patient/Person Reported Outcomes Core (RFA-OD-16-003), Administrative Supplements to the Children’s Health Exposure Analysis Resource (PA-16-046), IDeA States Pediatric Clinical Trials Network (RFA-OD-16-002 and  RFA-OD-16-001), and a Genetics Core to be released in FY17.

Funding for an exploratory UG3 phase will be used for planning, feasibility testing, and developing study documents, including the study protocol and Manual of Procedures. UG3 projects that have met milestones will be administratively considered for transition to the UH3 implementation phase. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases.

Award: NIH OD intends to commit up to $59M in FY2016 to fund 20-30 awards. Future year amounts will depend on annual appropriations and are anticipated to be no more than $123M for FY17; and $120M for FY18-22.

Direct costs should not exceed $1,000,000 in FY16 (year 1) only, and must be well justified and appropriate for the size of the cohort available. Budgets for FY17-22 (years 2-7) are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.  The project period may be up to 7 years; the proposed project may be up to 2 years for the first phase (UG3) and up to 5 years for the second phase (UH3).

Eligibility & Guidelines: Link

Announcement Expires: April 16, 2016


Title: Environmental Influences on Child Health Outcomes (ECHO) Data Analysis Center (U24)Announcement Number: RFA-OD-16-005

Deadline: March 15, 2016- Letter of Intent

April 15, 2016, by 5:00 PM local time of applicant organization- Application

Purpose: The purpose of this FOA is to support a Data Analysis Center (DAC) for the Environmental Influences on Child Health Outcomes (ECHO) program.  The ECHO DAC will provide the data repository and the data analysis functions for all common ECHO activities.

NIH is establishing the new ECHO program to investigate the longitudinal impact of prenatal, perinatal, and postnatal environmental exposures on pediatric health outcomes with high public health impact. To do so, NIH will support multiple synergistic, prospective longitudinal studies using extant cohorts that represent variable environmental exposures (e.g., physical, chemical, biological, behavioral, social). These studies will collaborate on standardization and collection of core data elements to answer research questions of how environmental exposures impact one or more of four key pediatric outcomes. The program will be overseen by a Steering Committee of Investigators and an NIH Program Director, and an External Scientific Board. A separate, but related research effort, will support an IDeA States National Pediatric Clinical Research Network to help address access gaps for rural children by leveraging the infrastructure at existing IDeA state centers.

Award: NIH intends to commit up to $5,000,000 in FY 2016 to fund one award. Application budgets are limited to $3,000,000 in direct costs for Year 1, $6,250,000 in direct costs for Year 2, and $9,500,000 in direct costs for other project years. Application budgets need to reflect the actual needs of the proposed project. The project period may not exceed 7 years. 

Eligibility & Guidelines: Link

Announcement Expires: April 16, 2016


Title: Environmental Influences on Child Health Outcomes (ECHO) Coordinating Center (U2C)

Announcement Number: RFA-OD-16-006

Deadline: March 15, 2016- Letter of Intent

April 15, 2016, by 5:00 PM local time of applicant organization- Application

Purpose: The purpose of this FOA is to support a Coordinating Center for the Environmental Influences on Child Health Outcomes (ECHO) program. The ECHO Coordinating Center will provide the organizational framework for the management, direction, and overall coordination of all common ECHO activities.

NIH is establishing the new ECHO program to investigate the longitudinal impact of prenatal, perinatal, and postnatal environmental exposures on pediatric health outcomes with high public health impact. To do so, NIH will support multiple synergistic, prospective longitudinal studies using extant cohorts that represent variable environmental exposures (e.g., physical, chemical, biological, behavioral, social). These studies will collaborate on standardization and collection of core data elements to answer research questions of how environmental exposures impact one or more of four key pediatric outcomes. The program will be overseen by a Steering Committee of Investigators and an NIH Program Director, and an External Scientific Board. A separate, but related, research effort will support an IDeA States National Pediatric Clinical Research Network to help address access gaps for rural children by leveraging the infrastructure at existing IDeA state centers.

Award: NIH intends to commit up to $15,000,000 in FY 2016 to fund one award. Future year amounts will depend on annual appropriations.

Application budgets are limited to $9,400,000 in direct costs for Year 1 and Year 5; and to $11,250,000 in direct costs for other project years including $1,900,000 each of those years for an ECHO Opportunities and Infrastructure Fund. Application budgets need to reflect the actual needs of the proposed project. The project period may not exceed 7 years.

Eligibility & Guidelines: Link

Announcement Expires: April 16, 2016


Title: Limited Competition: Exposure Analysis Services for the Environmental Influences on Children’s Health Outcomes (ECHO) Program (Admin Supplement)

Announcement Number: PA-16-046

Deadline: March 15, 2016- Letter of Intent

April 15, 2016, by 5:00 PM local time of applicant organization- Application

Purpose: This funding opportunity announcement (FOA) solicits applications for administrative supplements from the Children’s Health Exposure Analysis Resource (CHEAR) grantees in order to expand the service offerings of CHEAR to meet the analytical needs of the NIH Environmental influences on Children’s Health Outcomes (ECHO) program.

This is a limited competition FOA, available only to grantees funded by the Children’s Health Exposure Analysis Resource (CHEAR) National Exposure Assessment Laboratory Network (RFA-ES-15-009), Data Repository, Analysis and Science Center (RFA-ES-15-010), and Coordinating Center (RFA-ES-15-011).

Award: Application budgets must reflect the actual needs of the proposed project.The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes. The project and budget periods must be within the currently approved project period for the existing parent award.

Eligibility & Guidelines: Link

Announcement Expires: April 16, 2016


Title: Oral HIVacc: Oral Mucosal Immunization Approaches for HIV Prevention (R01)
Announcement Number: RFA-DE-16-006
Deadline: Letter of Intent- October 24, 2015
Application- November 24, 2015
Purpose: This Funding Opportunity Announcement (FOA) solicits research projects to develop and test novel HIV vaccines for direct administration into oral lymphoid tissues to trigger protective, local and systemic immunity.  Specifically, this FOA seeks research projects to: 1) define the mechanisms by which direct HIV vaccination of oral lymphoid tissues induce oral innate as well as local and systemic adaptive immune responses; 2) determine the mechanisms by which new adjuvants used together with oral HIV vaccine candidates enhance local and systemic immunity; 3) test innovative, oral vaccine vectors expressing HIV vaccine antigens to trigger protective immunity; 4) compare different HIV vaccine immunization strategies and schemes for the oral mucosa to maximize protection; and 5) delineate the role of dynamic changes in oral and immune cell subsets and their interactions to enhance immunity upon oral HIV vaccination.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is 5 years.
Eligibility & Guidelines: Link
Announcement Expires: November 24, 2016

Title: Imaging Diagnostics of Dental Diseases and Conditions (Caries, Periodontal Disease, Cracked Teeth, and Pulp Vitality) (R43/R44) (R41/R42)
Announcement Number: (R43/R44) PA-15-335
(R41/R42) PA-15-336
Deadline: Standard dates apply, by 5:00 PM local time of applicant organization. October 5, February 5, June 5
Purpose: The intent of this SBIR initiative reissue is to accelerate the advanced development and clinical implementation of reliable, reproducible, highly specific and sensitive imaging diagnostic devices for dental caries, periodontal disease, cracked teeth, and pulp vitality. These new devices must demonstrate superior specificity and sensitivity compared with current diagnostic methods, such as the visual/tactile/radiographic examination for detection of caries, while not increasing health risks for patients. Approaches that could be explored include, but are not limited to: optical coherence tomography (OCT) with or without Raman spectroscopy, MRI image analysis, electrical conductivity measurement (ECM), quantitative laser fluorescence (QLF), alternating current impedance spectroscopy, multi-photon imaging, infrared thermography, infrared fluorescence (IR), ultrasound, and terahertz imaging.  The development of novel modalities is also encouraged.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.  With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% ($225,000 for Phase I and $1,500,000 for Phase II). As written in the statute and under appropriate circumstances, NIH can apply for a waiver from SBA to issue an award exceeding $225,000 for Phase I or $1,500,000 for Phase II, if this cap will interfere with NIH‘s ability to meet its mission. Award waivers from the SBA are not guaranteed and may delay the release of funds. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Eligibility & Guidelines: (R43/R44) (R41/R42)Announcement Expires:  September 8, 2018


 

Title: Advanced Development of Informatics Technologies for Cancer Research and Management (U24)
Announcement Number: PAR-15-331
Deadline: November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included.
Award: The amount of requested budget may not exceed $600,000 Direct Costs (excluding consortium F&A costs) per year. Letter of Intent is due 30 days before the application due date.
Eligibility & Guidelines: Link
Announcement Expires: June 15, 2018


 

Title: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01)
Announcement Number: PAR-15-332
Deadline: November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included.
Award: Budgets are limited to $300,000 Direct Costs (excluding consortium F&A costs) per year. Letter of Intent is due 30 days before the application due date.
Eligibility & Guidelines:  Link
Announcement Expires: June 15, 2018


 

Title: Sustained Support for Informatics Resources for Cancer Research and Management (U24)
Announcement Number: PAR-15-333
Deadline: November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources.  This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field.  In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.  The maximum project period is five years. Letter of Intent is due 30 days before the application due date.
Eligibility & Guidelines:  Link
Announcement Expires: June 15, 2018


 

Title: Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21)
Announcement Number: PAR-15-334
Deadline: November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant (R21) applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities.  As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Initiative, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed informatics method or algorithm must have a clear rationale on why it is novel and how it will benefit the cancer research field. Potential applicants who are interested in more downstream tool development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.
Award: Direct costs are limited to $275,000 over a two year period. No more than $200,000 may be requested in any single year. The maximum project period is two years.
Eligibility & Guidelines: Link
Announcement Expires: June 15, 2018

Title: Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)
Announcement Number: PA-15-321
Deadline: Due dates may vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details.
Purpose: The Office of Research on Women’s Health (ORWH) and participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) announce the continuation of the program for administrative supplements to research grants to support individuals with high potential to re-enter an active research career after an interruption for family responsibilities or other qualifying circumstances. The purpose of these supplements is to encourage such individuals to re-enter research careers within the missions of all the program areas of NIH. This program will provide administrative supplements to existing NIH research grants for the purpose of supporting full-time or part-time research by these individuals to update their existing research skills and knowledge.
Award: Individual(s) must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support. The requested salary and fringe benefits for a re-entry candidate must be in accordance with the salary structure of the grantee institution, consistent with the level of effort. An additional amount up to $10,000 may be requested for supplies, domestic travel, and publication costs relevant to the proposed research. Equipment may not be purchased as a part of this supplement without justification and specific prior approval of the NIH awarding component.The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes.
Eligibility & Guidelines: Link
Announcement Expires: September 30, 2018

Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)
Announcement Number: PA-15-322
Deadline: Due dates may vary by awarding IC.  See Table of IC-Specific Information, Requirements and Staff Contacts for more details.
Purpose: The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.  Administrative supplements must support work within the scope of the original project.
Award: Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. Direct costs for individual administrative supplements vary from less than $5,000 to more than $100,000 depending on the career level of the candidate. Administrative supplements end with the competitive cycle of the parent grant. Budget requests may also be limited by the awarding IC.  See Table of IC-Specific Information, Requirements and Staff Contacts for more details.The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes.The project and budget periods must be within the currently approved project period for the existing parent award.Eligibility & Guidelines: Link
Announcement Expires: September 30, 2018


 

Title: Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01) (R21)
Announcement Number: (R01) PAR-13-379
(R21) PAR-13-380
Deadline: Standard dates apply, by 5:00 PM local time of applicant organization.  (R01) Oct 5, Feb 5, June 5
(R21) Oct 16, Feb 16, June 16
Purpose:  The goal of this funding opportunity announcement is to support the development of well-founded outcome measures, including establishing their reliability and validity, for clinical studies of oral and craniofacial diseases and conditions.
Award: (R01) The scope of the proposed project should determine the project period. The maximum project period is 5 years. Application budgets are not limited, but need to reflect the actual needs of the proposed project.
(R21) The combined budget for direct costs for the two year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year. The total project period may not exceed two years.
Eligibility & Guidelines: (R01) (R21) 
Announcement Expires: September 8, 2015

Title: Establishing Behavioral and Social Measures for Causal Pathway Research in Dental, Oral and Craniofacial Health (R01) (R21)
Announcement Number: (R01) PAR-14-143(R21) PAR-14-144
Deadline: (R21) Standard dates apply:
New: February 16, June 16, October 16
Resubmission, Revision: March 16, July 16, November 16
(R01) Standard dates apply:
New: February 5, June 5, October 5
Resubmission, Revision: March 5, July 5, November 5
Purpose: The purpose of this funding opportunity announcement is to encourage the establishment of psychometrically-sound measures of specific behavioral or social phenomena that can be used to test causal hypotheses about behavioral and social contributors to dental, oral or craniofacial diseases. Measures can be developed de novo, or adapted from existing measures, e.g., those used in other fields or for different purposes. In either case, applications should include appropriate psychometric tests of the measure(s), and testing for acceptability of use with the target population. This announcement calls for the development of two types of measures: 1) measures of the health behaviors, social interactions, community characteristics, built environments, etc., targeted by behavioral or social interventions to improve oral health; and 2) measures of the hypothesized moderators and mediators of a behavioral or social intervention’s effect.
Award: (R21) The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period. The total project period for an application submitted in response to this funding opportunity announcement may not exceed 2 years. (R01) The total project period for an application submitted in response to this funding opportunity announcement may not exceed 5 years. Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility and Guidelines:
(R21)->Link
(R01)
Announcement Expires: May 8, 2017


Title: NIH Director’s New Innovator Award Program (DP2)
Announcement Number: RFA-RM-13-007
Deadline: October 16, 2015, by 5:00 PM local time of applicant organization.
Purpose: The NIH Director’s New Innovator Award addresses two important goals: stimulating highly innovative research and supporting promising new investigators. New investigators may have exceptionally innovative research ideas, but not the preliminary data required to fare well in the traditional NIH peer review system. As part of NIH’s commitment to increasing opportunities for new scientists, it has created the NIH Director’s New Innovator Award to support exceptionally creative new investigators who propose highly innovative research projects that have the potential for unusually high impact. This award complements ongoing efforts by NIH and its Institutes and Centers to fund new investigators through R01 grants and other mechanisms.
The NIH Director’s New Innovator Award program is different from traditional NIH grants in several ways. It is designed specifically to support unusually creative investigators with highly innovative research ideas at an early stage of their career when they may lack the preliminary data required for an R01 grant application. The emphasis is on innovation and creativity; preliminary data are not required, but may be included. No detailed, annual budget is requested in the application. The review process emphasizes the individual’s creativity, the innovativeness of the research approaches, and the potential of the project, if successful, to have a significant impact on an important biomedical or behavioral research problem.
The research proposed for a New Innovator Award may be in any scientific area relevant to the mission of NIH (biological, behavioral, clinical, social, physical, chemical, computational, engineering, and mathematical sciences). Investigators who were not selected for an award in prior years may submit applications this year as long as they retain their ESI (early stage investigator) eligibility; however, all applications must be submitted as “new” applications regardless of any previous submission to the program.
Award: Awards are multi-year funded and will be for up to the equivalent of $300,000 in Direct Costs each year for five years, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award. The maximum project period is 5 years.
Eligibility & Guidelines: Link
Announcement Expires: October 17, 2015


Title: Self-Management for Health in Chronic Conditions (R15)
Announcement Number: PA-14-345
Deadline: February 25, June 25, October 25 Standard dates apply, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this initiative is to support research in self-management focused across conditions. A recent report from the Institute of Medicine (IOM) identifies the epidemic of chronic condition as the nation’s leading health challenge and calls for cross-cutting, coordinated public health actions for “living well with chronic illness”. This Funding Opportunity Announcement (FOA) addresses that recommendation by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses/conditions. Self-management is the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences associated with a chronic illness or condition.
Award: Applicants may request up to $300,000 in direct costs plus applicable Facilities & Administrative (F&A)/indirect costs for the entire project period of up to 3 years. Note when a consortium is involved, the $300,000 direct cost limit is exclusive of consortium F&A costs. These can be requested in addition to the $300,000 direct costs limit. The maximum project period is 3 years.
Eligibility & Guidelines: Link
Announcement Expires: January 8, 2018


Title: Biology of the Temporomandibular Joint in Health and Disease (R21)
Announcement Number: PA-14-359
Deadline: October 16, February 16, June 16 Standard dates apply, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this FOA is to encourage research that will advance our understanding of the temporomandibular joint (TMJ) in health and disease and to stimulate research that complements previous efforts and focuses on the biology of joint function and the tissues that make up the TMJ. A better understanding of total joint structure and mechanics including the interactions of the skeletal, muscular, nervous, immune, and circulatory systems using new in vivo and in vitro models is needed. An expected outcome of this FOA is new knowledge that will provide a basis for developing novel approaches to prevent, diagnose, assess risk, and treat temporomandibular joint disorder (TMD)
Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period.
Eligibility & Guidelines: Link
Announcement Expires: September 8, 2017


Title: Advancing Interventions to Improve Medication Adherence (R21)
Announcement Number: PA-14-335
Deadline: October 16, February 16, June 16
Standard dates apply, by 5:00 PM local time of applicant organization.
Purpose: This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes. This FOA encourages Exploratory/Developmental Research Project Grant (R21) applications for research and development of interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Applicants should demonstrate the feasibility of collecting multi-modal data on the targets of the intervention including: a patient self-report of medication adherence, at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.), and a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered. Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism. The National Cancer Institute (NCI) is interested in basic and applied research in the behavioral, social, and population sciences to create or enhance interventions that reduce cancer risk, incidence, morbidity and mortality, and improve quality of life.
Award: The combined budget for the direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
Eligibility & Guidelines: Link
Announcement Expires: January 8, 2018


Title: Immune System Plasticity in the Pathogenesis and Treatment of Complex Dental, Oral, and Craniofacial Diseases (R01)
Announcement Number: PAR-15-192
Deadline: Standard dates (June 5, October 5, February 5) apply, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage research projects to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial diseases. The goal is to advance knowledge of the immunological basis of dental, oral, and craniofacial diseases, and to develop tools and technologies for precise modulation of the immune system to restore or maintain health. The expectation is that new knowledge derived from this research will facilitate development of novel immunomodulatory therapies to prevent disease onset or reverse disease progression.
Specific areas of interest as they are applied to DOC diseases and conditions include, but are not limited to:
Identification of genetic loci and environmental factors
• Development of systems biology approaches to understand innate and adaptive immune responses and plasticity within the context of tissue homeostasis in health and disease, identification of key signaling molecules and networks that can serve as effective diagnostic and therapeutic targets, and development of tools and technologies to permit precise manipulation of these targets to restore health.
• Development of new and improvement of existing animal models reflecting the pathogenesis of human inflammatory diseases
• Development of experimental tools and technologies for precise and predictable modulation of immune system plasticity and functions
• Advancement in the understanding of endogenous cellular and molecular mediators that maintain normal tissue homeostasis, prevent inflammatory disease progression, and initiate and control inflammatory responses, immune activation, and microbial translocation in oral infections, including those that control transition from acute to chronic conditions.
• Development of treatment or prevention for DOC diseases based on precise modulation of immune system plasticity and functions, and identification of optimal conditions for fighting infections, pathological immune activation, and aberrant inflammation.
Studies that propose the testing of immune modulators that are already in early or late phases of clinical trials are discouraged unless proposed in the context of studying combination therapies with other novel targeted agents; studies that involve the testing of novel immuno-modulators are strongly encouraged.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Eligibility & Guidelines: Link
Announcement Expires: September 8, 2018


Title: Immune System Plasticity in the Pathogenesis and Treatment of Complex Dental, Oral, and Craniofacial Diseases (R21)
Announcement Number: PAR-15-193
Deadline: Standard dates (June 16, October 16, February 16) apply, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage research projects to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial diseases. The goal is to advance knowledge of the immunological basis of dental, oral, and craniofacial diseases, and to develop tools and technologies for precise modulation of the immune system to restore or maintain health. The expectation is that new knowledge derived from this research will facilitate development of novel immunomodulatory therapies to prevent disease onset or reverse disease progression.
Award: Specific areas of interest as they are applied to DOC diseases and conditions include, but are not limited to:
• Identification of genetic loci and environmental factors, including host genome interactions with the microbiome, that contribute to immune dysfunction and pathological immune system plasticity associated with DOC diseases.
• Development of systems biology approaches to understand innate and adaptive immune responses and plasticity within the context of tissue homeostasis in health and disease, identification of key signaling molecules and networks that can serve as effective diagnostic and therapeutic targets, and development of tools and technologies to permit precise manipulation of these targets to restore health.
• Development of new and improvement of existing animal models reflecting the pathogenesis of human inflammatory diseases.
• Development of experimental tools and technologies for precise and predictable modulation of immune system plasticity and functions
• Advancement in the understanding of endogenous cellular and molecular mediators that maintain normal tissue homeostasis, prevent inflammatory disease progression, and initiate and control inflammatory responses, immune activation, and microbial translocation in oral infections, including those that control transition from acute to chronic conditions.
• Development of treatment or prevention for DOC diseases based on precise modulation of immune system plasticity and functions, and identification of optimal conditions for fighting infections, pathological immune activation, and aberrant inflammation.
Studies that propose the testing of immune modulators that are already in early or late phases of clinical trials are discouraged unless proposed in the context of studying combination therapies with other novel targeted agents; studies that involve the testing of novel immuno-modulators are strongly encouraged.
Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
Eligibility & Guidelines: Link
Announcement Expires: September 8, 2018


Title: Biological and Physiological Effects of E-cigarette Aerosol Mixtures (R01)(R21)
Announcement Number: (R01)RFA-DE-16-004 (R21)RFA-DE-16-005
Deadline: July 28, 2015, by 5:00 PM local time of applicant organization.
Purpose: (R01) The purpose of this Funding Opportunity Announcement (FOA) is to support research aimed at understanding the biological and physiological effects of aerosol mixtures produced by electronic cigarettes (ECs) on cells, tissues and organs of the oral cavity including oral and periodontal epithelia, gingiva, salivary glands, and tooth. This FOA will also support research on elucidation of the effects of ECs on oral microbiome. Research supported by this FOA would provide essential and necessary information on the biological effects of ECs that would in turn lead to evidence based foundational information for health policy decisions. Topics of interest to NIDCR will include the following:
• Determination of the synergistic biological effects of EC aerosol mixtures on cells, tissues and organs of the oral cavity using appropriate in vitro and in vivo model systems;
• Analysis of genotoxicity/DNA damage, cellular metabolism, mutagenicity, and/or transformation potential, effects on cell proliferation and cell death, of EC aerosol mixtures using appropriate in vitro and/or in vivo model systems with an emphasis on oral and periodontal epithelial cells;
• High throughput analysis (e.g. genomic, epigenomic and proteomic analyses) to understand the biological and physiological effects of EC aerosols on cells, tissues and organs of the oral cavity;
• Examination and comparison of the effects on oral and/or periodontal epithelial cells in chronic users of ECs, smokers of combustible cigarettes and non-smokers;
• Analysis of effects of ECs on factors responsible for the maintenance of oral homeostasis such as cytokine production and downstream signaling pathways, immune cell function, and oral microbiome; and
• Assessment of effects of ECs on salivary gland function, saliva flow; and on dental/periodontal health using appropriate in vivo model systems. (R21) The goal of this FOA is to encourage studies aimed at assessing the biological and physiological effects of EC aerosol mixtures on cells, tissues and organs of the oral cavity.
Award: Application budgets are limited to $250,000 per year in directs costs and need to reflect the actual needs of the proposed project. The project period is limited to 4 years. NIH intends to fund an estimate of 3-4 awards, corresponding $3 million, for fiscal year 2016. Future year amounts will depend on annual appropriations.
Eligibility & Guidelines: Link
Announcement Expires: July 29, 2015


Title: Advancing Interventions to Improve Medication Adherence (R01)
Announcement Number: PA-14-334
Deadline: (R01)February 5, June 5, October 5 (R21) October 16, February 16, June 16 Standard dates apply, by 5:00 PM local time of applicant organization.
Purpose: This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes and Centers. This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered
The National Cancer Institute (NCI) is interested in basic and applied research in the behavioral, social, and population sciences to create or enhance interventions that reduce cancer risk, incidence, morbidity and mortality, and improve quality of life.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Link
Announcement Expires: January 8, 2018


Title: NIDCR Behavioral or Social Intervention Clinical Trial Planning Grant (R34)
Announcement Number: PAR-14-342
Deadline: October 16, February 16, June 16
Purpose: The NIDCR recognizes that behavioral and social factors play a role in many dental, oral and craniofacial (DOC) disorders and conditions, and that behavioral and social interventions have the potential to improve these conditions by targeting key behavioral and social factors. The NIDCR is committed to supporting the development and testing of behavioral and social interventions to improve DOC health, and to supporting careful planning for these intervention studies. The purpose of this FOA is to provide support for planning well-designed, rigorously-conducted behavioral or social intervention studies relevant to DOC health. The R34 grant will support activities that include, but are not limited to: the development of the behavioral or social intervention manual and procedures for training interventionists; development of the clinical protocol that will guide a subsequent clinical trial; the tools for data management, participant safety and operational oversight; and other activities to prepare for a subsequent clinical trial. R34 applications preparing for a behavioral or social intervention study may involve human subjects as part of small-scale testing of the feasibility and acceptability of the intervention(s), measures, methods, training approaches, etc. However, the R34 planning grant is not meant to support efficacy testing of interventions.
Award: Direct costs may not exceed $150,000. The total project period may not exceed one year.
Eligibility & Guidelines: Link
Announcement Expires: September 8, 2017


Title: NIDCR Clinical Trial or Biomarker Clinical Validation Study Planning Grant (R34)
Announcement Number: PAR-14-346
Deadline: October 16, February 16, June 16 apply, by 5:00 PM local time of applicant organization.
Purpose: The NIDCR is committed to identifying effective approaches to address dental, oral and craniofacial diseases and disorders. Improving health through the generation of robust data from well-designed and executed clinical trials and clinical studies is a high priority for the NIDCR. To meet this goal, the NIDCR strongly encourages investigators proposing investigator-initiated interventional clinical trials or biomarker clinical validation studies to utilize a two-part grant process: Part 1: The NIDCR Clinical Trial or Biomarker Clinical Validation Study Planning Grant (R34). The NIDCR will support clinical trial or biomarker clinical validation study planning grants (R34) for comprehensive planning, design and documentation of investigator-initiated Phase I, II, III, or IV clinical trials, or biomarker clinical validation studies that involve prospective collection of specimens and clinical outcomes. Part 2: The NIDCR Clinical Trial or Biomarker Clinical Validation Cooperative Agreement (U01). The NIDCR will accept, peer review, and consider for funding applications for Clinical Trial Implementation or Biomarker Clinical Validation Study Cooperative Agreements (U01) submitted to PAR-11-339. The material in the implementation or validation grant application must be sufficient to demonstrate adequate preparation for launching a study, i.e., that initiation of study staff training, followed by subject recruitment can begin upon award of the cooperative agreement and approval of the study protocol by the oversight committee.
Award: Direct costs may not exceed $150,000. The total project period may not exceed one year.
Eligibility & Guidelines: Link
Announcement Expires: September 8, 2017


Title: Self-Management for Health in Chronic Conditions (R01)
Announcement Number: PA-14-344
Deadline: February 5, June 5, October 5 Standard dates apply, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this initiative is to support research in self-management focused across conditions. A recent report from the Institute of Medicine (IOM) identifies the epidemic of chronic condition as the nation’s leading health challenge and calls for cross-cutting, coordinated public health actions for “living well with chronic illness”. This Funding Opportunity Announcement (FOA) addresses that recommendation by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses/conditions. Self-management is the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences associated with a chronic illness or condition.
Award: The maximum project period is 5 years.
Eligibility & Guidelines: Link
Announcement Expires: January 8, 2018


Title: Biology of the Temporomandibular Joint in Health and Disease (R01)
Announcement Number: PA-14-358
Deadline: February 5, June 5, October 5
Purpose: The purpose of this FOA is to encourage research that will advance our understanding of the temporomandibular joint (TMJ) in health and disease and to stimulate research that complements previous efforts and focuses on the biology of joint function and the tissues that make up the TMJ. A better understanding of total joint structure and mechanics including the interactions of the skeletal, muscular, nervous, immune, and circulatory systems using new in vivo and in vitro models is needed. An expected outcome of this FOA is new knowledge that will provide a basis for developing novel approaches to prevent, diagnose, assess risk, and treat temporomandibular joint disorder (TMD).
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.
Eligibility & Guidelines: Link
Announcement Expires: September 8, 2017


Title:Interventions for Health Promotion and Disease prevention in Native American Populations (R01)
Announcement Number: PA-14-260
Deadline: May 12, 2015; May 12, 2016; May 12, 2017, by 5:00 PM local time of applicant organization.
Purpose: The purpose of this funding opportunity announcement (FOA) is to develop, adapt, and test the effectiveness of health promotion and disease prevention interventions in Native American (NA) populations. NA populations are exposed to considerable risk factors that significantly increase their likelihood of chronic disease, substance abuse, mental illness, oral diseases, and HIV-infection. The intervention program should be culturally appropriate and promote the adoption of healthy lifestyles, improve behaviors and social conditions and/or improve environmental conditions related to chronic diseases, the consumption of tobacco, alcohol and other drugs, mental illness, oral disease, or HIV-infection. The intervention program should be designed so that it could be sustained within the entire community within existing resources, and, if successful, disseminated in other Native American communities. The long-term goal of this FOA is to reduce mortality and morbidity in NA communities. For the purposes of this FOA Native Americans include the following populations: Alaska Native, American Indian, and Native Hawaiian. The term ‘Native Hawaiian’ means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.
Award: The project period is limited to five years. Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Link
Announcement Expires: August 25, 2017


Title: Imaging and Biomarkers for Early Cancer Detection (R01)
Announcement Number: PAR-13-189
Deadline: December 11, 2014; July 10, 2015; December 11, 2015
Purpose: This Funding Opportunity Announcement (FOA) invites research project (R01) applications that combine imaging and biomarkers. The overall objective of this FOA is to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and diagnosis by integrating multi-modality imaging strategies and multiplexed biomarker methodologies.
Award: Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is 5 years.
Eligibility and Guidelines: Link
Announcement Expires: December 12, 2015

Title: Detection of Pathogen-Induced Cancer (DPIC) (R01)
Announcement Number: PAR-13-190
Deadline: December 11, 2014; July 10, 2015; December 11, 2015
Purpose: This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to encourage research projects which focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.
Award: Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is 5 years.
Eligibility and Guidelines: Link
Announcement Expires: December 12, 2015

Title: NIH Science Education Partnership Award (SEPA) (R25)
Announcement Number: PAR-14-228
Deadline: June 22, 2016 by 5:00 PM local time of applicant organization.
Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The goal of the Science Education Partnership Award (SEPA) program is to invest in educational activities that enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To this end, this funding opportunity announcement (FOA) encourages the development of innovative educational activities for pre-kindergarten to grade 12 (P-12), teachers and students from underserved communities with a focus on Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development or Informal science Education (ISE) exhibits, and Outreach activities.
Award: Direct costs are limited to $250,000 annually. F&A will be budgeted and reimbursed at a rate of 8 percent of modified total direct costs, exclusive of tuition and fees, health insurance (when awarded as part of tuition and fees), expenditures for equipment, and consortia in excess of $25,000. The project period may not exceed 5 years.
Eligibility and Guidelines: Link
Announcement Expires: June 23, 2016


Title: NIH Support for Conferences and Scientific Meetings (Parent R13/U13)
Announcement Number: PA-13-347
Deadline: April 12, August 12, December 12
Purpose: The purpose of the NIH Research Conference Grant (R13) and NIH Research Conference Cooperative Agreement (U13) Programs is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.
Award: Most ICs will accept applications for up to 5 years of support when a series of annual or biannual conferences are proposed by a permanently sponsoring organization. Support for conferences held on a less frequent schedule must be applied for individually.
Eligibility and Guidelines: Link
Announcement Expires: September 8, 2016


Title: AHRQ Conference Grant Program (R13)
Announcement Number: PA-13-017
Deadline: February 1, May 1, August 1, and November 1 annually, beginning February 1, 2013
Purpose: The Agency for Healthcare Research and Quality (AHRQ), announces its interest in supporting conferences through the AHRQ Conference Grant Program. AHRQ seeks to support conferences that help to further its mission to improve the quality, safety, efficiency, and effectiveness of health care for all Americans. The types of conferences eligible for support include:
Research development – conferences where issues or challenges in the practice and delivery of health care are defined and a research agenda or strategy for studying them is developed;
Research design and methodology – conferences where methodological and technical issues of major importance in the field of health services research are addressed or new designs and methodologies are developed;
Dissemination and implementation conferences – conferences where research findings and evidence-based information and tools are summarized, communicated and used by organizations and individuals that have the capability to use the information to improve the outcomes, quality, access to, and cost and utilization of health care services; and/or;
Research training, infrastructure and career development – conferences where faculty, trainees and students are brought together with stakeholders to develop, share or disseminate research products, experiences, curricula, syllabi, training competencies. These types of conferences are not for the training of individuals in health services research.
Award: The total costs for a grant awarded under this Funding Opportunity Announcement will not exceed $35,000 annually. Facilities and administrative costs (indirect costs) are not allowed for conference grants.
Guidelines: Link


Title: Research on Alcohol and HIV/AIDS (R01) (R03) (R21)
Announcement Number: (R01)PA-13-121; (R03)PA-13-120; (R21) PA-13-122
Deadline:
(R01)Sept 7, Jan 7, May 7
(R03)Feb 16, June 16, Oct 16
(R21)Feb 16, June 16, Oct 16
Purpose This Funding Opportunity Announcement (FOA) is intended to appeal to a broad audience of alcohol and HIV/AIDS researchers, including alcohol researchers with no prior experience in HIV/AIDS research but with a keen appreciation for the relationship between problem drinking and HIV/AIDS and a b interest in acquiring such experience; HIV/AIDS researchers with no prior alcohol research experience who realize the importance of more intensive alcohol interventions to improving clinical outcomes among HIV-infected individuals; and those with prior research experience in the area of co-occurring HIV/AIDS and alcohol and other substance abuse. The primary objective for this announcement is to support small research projects : 1) to characterize the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV in order to identify and apply appropriate alcohol and HIV interventions as public health measures; 2) to more fully understand and prevent the progression of HIV disease in the presence of continued alcohol exposure; and 3) to develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations (e.g. minority women, young gay men, etc.), and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.
Award: (R01) Application budgets are not limited, but need to reflect actual needs of the proposed project; (R03) Budgets for direct costs of up to $50,000 per year and a project duration of up to two years may be requested for a maximum of $100,000 direct costs over a two-year project period; (R21) Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.
Eligibility and Guidelines:
(R01)
(R03)
(R21)
Announcement Expires: May 8, 2016

Title: Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)(R21)(R24)
Announcement Number: (R01)PAR-13-114; (R21)PAR-13-115; (R24)PAR-13-252
Deadline: NIH Standard Dates Apply
(R01)Feb 5, June 5, Oct 5
(R21)Feb 16, June 16, Oct 16
(R24)Jan 25, May 25, Sept 25
Purpose This FOA encourages Research Project Grant applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.
Award: (R01) (R24) Application budgets are not limited, but need to reflect the actual needs of the proposed project; (R21) The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period.
Eligibility and Guidelines: (R01) (R21) (R24)
Announcement Expires: (R01)May 8, 2016 (R21)May 8, 2016 (R24)September 8, 2016